Krebs Biochemicals and Industries bulk deals, insider trading and stake changes
NSE: KREBSBIOBSE: 524518Pharmaceuticals & BiotechnologySmall Cap
Formerly Krebs Biochemicals
Last close ₹51.85down ₹5.63 (9.79%)BSE ₹52.99
Share price at the NSE close on 23 Oct 2026. Previous close ₹57.48.
52-week range of traded prices to 23 Oct 2026
₹38.33Low, 30 Mar 2026₹76.85High, 5 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹112 Cr2,740th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- −14.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 27,82269.3% delivered
Krebs Biochemicals and Industries insider trading
All 16 disclosures on record. The company's own latest disclosure on record is from Apr 2021.Insider trading, all companies
Apr 2021
- Ipca Laboratories Limitedip₹17 Cr19,40,000 sharesReceived · Promoters · 6 Apr 2021 · Conversion of security · held 87,65,195 before, holds 1,07,05,195 after
May 2020
- Ipca Laboratories Limited₹14 Cr16,20,000 sharesReceived · Promoters · 20 May 2020 · Conversion of security · held 71,45,195 before, holds 87,65,195 after
Feb 2020
- Ipca Laboratories Limited₹12 Cr13,70,000 sharesReceived · Promoters · 5 Feb 2020 · Preferential Offer · held 57,75,195 before, holds 71,45,195 after
Mar 2019
- Ajay Ravi₹0.17 Cr19,488 sharesReceived · Promoter Group · 28 Mar 2019 · disclosed 29 Mar · Public Right · held 92,800 before, holds 1,12,288 after
- Hemalata Ravi₹4.02 Cr4,67,124 sharesReceived · Promoters · 28 Mar 2019 · disclosed 29 Mar · Public Right · held 22,24,400 before, holds 26,91,524 after
- Avinash Ravi₹3.19 Cr3,71,451 sharesReceived · Promoters · 28 Mar 2019 · disclosed 29 Mar · Public Right · held 17,68,821 before, holds 21,40,272 after
- Ipca Laboratories Limited₹14 Cr16,75,095 sharesReceived · Promoters · 26 Mar 2019 · disclosed 28 Mar · Public Right · held 41,00,100 before, holds 57,75,195 after
Sep 2017
- Avinash Ravi₹1.69 Cr1,79,316 sharesReceived · Immediate relative · 22 Sep 2017 · disclosed 29 Sep · Gift · stake 11.56% before, 12.87% after
- R T Ravi₹1.69 Cr1,79,316 sharesGave · Immediate relative · 22 Sep 2017 · disclosed 29 Sep · Gift · stake 1.44% before, 0.14% after
May 2016
- Hemalata Ravi₹3.67 Cr6,80,000 sharesReceived · Promoters · 28 May 2016 · disclosed 31 May · Preferential Offer · held 15,44,400 before, holds 22,24,400 after
Earlier, Oct 2015 to Nov 2015Hide earlier
Nov 2015
- Avinash Ravi₹0.05 Cr3,500 sharesReceived · Promoters · 20 Nov 2015 · disclosed 23 Nov · Inter-se-Transfer · held 15,83,405 before, holds 15,86,905 after
Oct 2015
- Avinash Ravi₹0.46 Cr35,000 sharesReceived · Promoter · 30 Oct 2015 · disclosed 3 Nov · Inter-se Transfer · held 15,48,405 before, holds 15,83,405 after
- Mohd. Vahidullah₹0.13 Cr10,000 sharesGave · Promoter · 30 Oct 2015 · disclosed 3 Nov · Off Market / Inter se transfer · held 10,000 before
- Samba Siva Rao Ravi₹0.33 Cr25,000 sharesGave · Promoter · 30 Oct 2015 · disclosed 3 Nov · Off Market / Inter se transfer · held 25,000 before
- Mrs Hemalata Ravi6,80,000unitsReceived · Promoter · 9 Oct 2015 · Convertible Warrants · Pref. Allotment · holds 6,80,000 after
- Hemalata Ravi6,50,000sharesReceived · Promoter · 3 Oct 2015 · disclosed 5 Oct · Pref. Allotment · held 89,440 before, holds 15,44,400 after
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Krebs Biochemicals and Industries stake sales and purchases
All 7 disclosures on record.
Apr 2021
- DisclosedIpca Laboratories Limited · promoterholds none after6 Apr 2021 · filed under the 2% rule · Preferential Allotment
- DisclosedIpca Laboratories Limited · promoterholds 49.65% after6 Apr 2021 · filed under the 2% rule · Preferential Allotment
May 2020
- AcquiredIpca Laboratories Limited · promoter4.98% of the company16,20,000 sharesholds 44.67% after20 May 2020 · filed under the 2% rule
Feb 2020
- AcquiredIPCA Laboratories Ltd · promoter7.61% of the company13,70,000 sharesholds 39.69% after5 Feb 2020 · filed under the 2% rule · Preferential Allotment
Mar 2019
- AcquiredAvinash Ravi along with PAC · promoter5.20% of the company8,63,989 sharesholds 29.93% after28 Mar 2019 · filed under the 2% rule
- AcquiredIPCA Laboratories Limited · promoter10.07% of the company16,75,095 sharesholds 34.73% after26 Mar 2019 · filed under the 2% rule
May 2016
- AcquiredHemalata Ravi · promoter4.95% of the company6,80,000 sharesholds 16.18% after28 May 2016 · filed under the 2% rule
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Krebs Biochemicals and Industries bulk deals
Last 12 months, since 23 Oct 2025: 2 bulk deals, ₹0.00 Cr bought and ₹0.80 Cr sold Bought and sold in deals. Each deal's shares times its price, added up for the buyers and apart for the sellers, so a block deal, which names both, counts on each side.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Thursday 1 Oct 20261 firm · ₹49,551 bought · ₹0.80 Cr soldNet sold ₹0.80 Cr
- Both waysVAIBHAV UPADHYAYBought 742 at ₹66.78Sold 1,20,268 at ₹66.690.56% of the companyNet −1,19,526 shares₹49,551 bought
Tuesday 26 Nov 20241 firm · ₹1.67 Cr bought · ₹0 soldNet bought ₹1.67 Cr
- BoughtGUTTIKONDA RAJASEKHARBought 1,43,843 at ₹115.850.67% of the company₹1.67 Cr
Friday 19 Jul 20242 firms · ₹5.63 Cr bought · ₹5.63 Cr soldNet sold ₹89,538
- Both waysNK SECURITIES RESEARCH PRIVATE LIMITEDBought 3,71,224 at ₹114.96Sold 3,71,224 at ₹115.161.72% of the companyNet nil₹4.27 Cr bought
- Both waysN.G.C.S. (P) LTD.Bought 1,17,638 at ₹115.39Sold 1,17,638 at ₹115.520.55% of the companyNet nil₹1.36 Cr bought
Friday 13 Aug 20211 firm · ₹0 bought · ₹3.35 Cr soldNet sold ₹3.35 Cr
- SoldBRESCON VENTURES PRIVATE LIMITEDSold 2,25,000 at ₹149.071.04% of the company₹3.35 Cr
Monday 28 Dec 20201 firm · ₹0 bought · ₹1.38 Cr soldNet sold ₹1.38 Cr
- SoldBRESCON VENTURES PRIVATE LIMITEDSold 1,00,000 at ₹137.750.51% of the company₹1.38 Cr
Friday 13 Oct 20171 firm · ₹0 bought · ₹0.82 Cr soldNet sold ₹0.82 Cr
- SoldRACHANADEVI RAJU AGARWALSold 91,270 at ₹90.000.66% of the company₹0.82 Cr
Wednesday 2 Jul 20141 firm · ₹0 bought · ₹0.11 Cr soldNet sold ₹0.11 Cr
- SoldNATIONAL ISURANCE CO LTDSold 56,563 at ₹20.02₹0.11 Cr
Friday 3 May 20131 firm · ₹0 bought · ₹0.07 Cr soldNet sold ₹0.07 Cr
- SoldANAPOTHANA VEMA TRUSTSold 71,730 at ₹9.50₹0.07 Cr
Thursday 6 Sep 20071 firm · ₹0 bought · ₹0.39 Cr soldNet sold ₹0.39 Cr
- SoldANAPOTHANA VEMA TRUSTSold 47,664 at ₹80.80₹0.39 Cr
Wednesday 17 Jan 20071 firm · ₹0 bought · ₹0.99 Cr soldNet sold ₹0.99 Cr
- SoldPASSIONATE INVESTMENT MANSold 99,743 at ₹99.05₹0.99 Cr
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 14 deals on record from 4 Jan 2004.